Solving the Unsolvable
Revolutionizing drug discovery at the molecular level
Built on the combined technology of Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, Transition Bio offers the only end-to-end condensate drug discovery engine built on molecular insights.
Our differentiated molecular platform…
Through our one-of-a-kind molecular lens, we unite droplet microfluidics and state-of-the art cellular imaging for novel drug discovery.
…delivers unique data…
Our data reveals the impact of chemical matter on condensate systems at the molecular level [cell image or droplet or phase diagram]
…and powers our technology.
Our pioneering machine learning/AI engine optimizes chemical.
News And Events
What’s New at Transition Bio
Transition Bio, Inc., a microfluidics- driven drug discovery platform company using biophysical…
Transition Bio, Inc. (the Company) today named several critical additions to its leadership team, including naming Gregory Miller as CEO…
Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined…
